Summary Cyclin Dl is a cell cycle regulator essential for G1 phase progression and is frequently overexpressed in several human tumour types as a consequence of gene amplification or chromosomal rearrangements. We analysed the expression of cyclin Dl in 75 patients with transitional cell carcinoma (TCC) to investigate the possible relationship between its expression and clinical outcome as well as histopathological findings using the immunohistochemical method. We observed strong staining (++, > 50% positive cells) for cyclin Dl in 19 cases (25.3%) and weak staining (+, 5-50% positive cells) in 19 cases (25.3%). Overexpression of cyclin Dl was not associated with tumour invasion. No significant association was found between overexpression of cyclin Dl and tumour grade (P > 0.05). We assessed the differences of disease-free interval in superficial tumours and actuarial survival probability in invasive tumours according to the status of cyclin Dl expression. Tumours with (++) staining for cyclin Dl recurred much more rapidly than (-) and/or (+) staining tumours (P < 0.01 for -vs ++; P < 0.05 for + vs ++). However, overexpression of cyclin Dl was not associated with a shortened overall survival of patients with invasive tumours (P< 0.1). These results suggest that genetic alteration of cyclin Dl appears to be an early event in the tumorigenesis of bladder TCC and is associated with early recurrence in superficial tumours.
Transitional cell carcinoma of the urinary bladder, like many other types of solid tumours, is expected to arise through a series of genetic changes that lead to tumour progression. The identification of the molecular events underlying urothelial cell transformation may not only expand our understanding of the natural history of the disease but may also present useful prognostic markers and potential targets for therapy.
Recent evidence suggests that amplification of the 1 1q 13 region is involved in a variety of human tumours, including bladder carcinoma (Proctor et al, 1991; Bringuier et al, 1996) , head and neck squamous cell carcinoma (Michalides et al, 1995) and carcinomas of the oesophagus and breast Jiang et al, 1992; Michalides et al, 1996) . In the amplified 1 1q13 region, several genes have been identified, of which cyclin Dl is most consistently amplified and overexpressed (Schuuring et al, 1992a) . Cyclins are thought to be essential proteins in cell cycle regulation because of their specific and periodic expression during cell cycle progression (Evans et al, 1983) . Binding of the cyclins with cyclin-dependent kinase regulates their activity and contributes to cell cycle regulation . Cyclin Dl is encoded by the CCND1 gene on chromosome 1 1q13 (Inaba et al, 1992; Xiong et al, 1992a) , which has been identified as the PRADI proto-oncogene and the most likely candidate for the BCL1 proto-oncogene (Motokura et al, 1991; Withers et al, 1991) .
Several studies have addressed the clinical and prognostic significance of amplification of 1lq13 loci. Amplification of cyclin Dl appears to be correlated with poor prognosis in breast carcinoma (Schuuring et al, 1992b) , with lymph node involvement and recurrence in head and neck squamous cell carcinoma (Muller et al, 1994; Parise et al, 1994; Michalides et al, 1995) . Although amplification of the 1 q13 region has been observed in bladder carcinoma, the prognostic significance of cyclin Dl overexpression has not been yet reported in bladder carcinoma. The purpose of this study was to detect the expression of cyclin DI in bladder carcinoma tissues and to investigate whether overexpression of cyclin Dl is associated with poor prognosis in patients with bladder carcinoma. For these purposes, we analysed overexpression of cyclin Dl immunohistochemically and reviewed the medical records of 75 patients retrospectively. The relationship of cyclin Dl overexpression to selected clinical variables was also analysed.
MATERIALS AND METHODS Patients
Primary bladder carcinomas from 75 patients were examined (age range 30-83 years; average 62 years). The tumours were staged according to the TNM pathological staging system (UICC, 1978) , and the histological grade was assessed according to Ash (1940) . The histopathological characteristics are summarized in Table 1 . Twenty of the 53 patients with superficial tumours had two or more tumours initially, and concomitant Tis (carcinoma in situ) lesions were not detected in the patients with superficial tumours. All patients were treated with curative intent and had received no prior therapy. Nine patients with solitary, low-grade and Ta tumours were treated with transurethral resection (TUR) only. Patients with multiple, high-grade Ta or TI tumours had received intravesical chemotherapy with doxorubicin (37 cases) or BCG (seven cases) after TUR. In 22 patients with invasive tumour, a total of ten patients underwent radical cystectomy, seven patients (Michalides et al, 1995) . Only nuclear staining was observed.
Statistics
The chi-square test for trend was used to evaluate the statistical significance of the relationship between staining and prognostic variables. Survival curves were prepared using the method of Kaplan and Meier (1958) . The statistical analyses of the differences between curves were performed using the log-rank test (Peto et al, 1977) .
RESULTS

Immunohistochemical staining for cyclin Dl
Tumour cell nuclear staining of variable extent was noted in 38 tumours (50.6%), which could be readily divided into groups showing weak (+) and strong staining (++) (Figure 1 
Prognostic significance of overexpression of cyclin Dl in superficial tumours
Nine of 14 superficial tumours (64%) with strong staining for cyclin DI recurred within 12 months. On the other hand, only 4 of 26 superficial tumours (15%) with negative staining and 2 of 13 superficial tumours (15%) with weak staining recurred within 12 months (CD1-vs ++, P < 0.01; + vs ++, P < 0.05; Figure 2 ). In nine patients treated with TUR only, three recurred during the follow-up period. Two cases with negative staining for cyclin Dl recurred in the post-operative period at 22 months and 33 months respectively, whereas one case with strong staining recurred in the postoperative period at 6 months. In 44 patients with TUR and intravesical doxorubicin or BCG therapy, 8 of 12 superficial tumours (67%) with strong staining, 2 of 10 (20%) with weak staining and 3 of 22 (14%) with negative staining recurred within 12 months (CD1 -vs ++, P < 0.005; + vs ++, P < 0.05, Figure 3) . Hence, superficial tumours recurred much more rapidly when the primary tumours showed strong staining for cyclin DI compared with primary tumours showing negative or weak staining, regardless of treatment.
Prognostic significance of overexpression of cyclin Dl in invasive tumours
We assessed the actuarial survival probability in the 22 patients with invasive tumours according to the expression of cyclin Dl. Three-year actuarial survival rate in the cases with negative staining for cyclin D1 was approximately 65%. On the other hand, in the patients with weak and strong staining for cyclin DI, 3-year actuarial survival rate was about 26%. Thus, there was a tendency for patients with stained tumours to have a poorer prognosis than British Journal of Cancer (1997) 75(12) 
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